文献速递临床免疫分子诊断临床微生物

全自动光激发化学发光免疫平台高敏SARS-CoV-2抗原检测评估

Evaluation of a high-sensitivity SARS-CoV-2 antigen test on the fully automated light-initiated chemiluminescent immunoassay platform.
PubMed 文献 · Clin Chem Lab Med · 2023-01-19

研究评估了基于全自动光激发化学发光免疫分析(LiCA®)的高敏SARS-CoV-2抗原检测,验证其分析性能并与rRT-PCR比较。798对鼻拭子中,总灵敏度97.5%、特异性99.9%,总符合率99.6%(kappa 0.98),Ct≤37.8时阳性检出率100%。

要点

  • LiCA®抗原检测与rRT-PCR总符合率99.6%,灵敏度97.5%、特异性99.9%。
  • 检测限:活病毒培养0.07 TCID50/mL,灭活病毒1.07 TCID50/mL。
  • Ct≤37.8时阳性检出率100%,适用于大规模筛查。

核心结论

  • LiCA®系统为鼻拭子SARS-CoV-2抗原检测提供了高灵敏度全自动平台,可作为rRT-PCR替代用于大规模筛查。

研究设计与样本

  • 验证LiCA®抗原检测的分析性能,使用不同类型核衣壳蛋白样本确定检测限。
  • 收集住院患者和无症状筛查者共798对前鼻拭子,与rRT-PCR进行一致性评估。

主要发现

  • 重复性和实验室内精密度为1.6-2.3%,C5∼C95区间偏离C50为-5.1-4.6%。
  • 检测限(均值±SD):国家参考品325±141 U/mL,活病毒培养0.07±0.04 TCID50/mL,重组核衣壳蛋白0.27±0.09 pg/mL,灭活病毒悬液1.07±1.01 TCID50/mL。
  • LiCA检测的病毒抗原水平中位数比对比快速检测低374倍(IQR 137-643)。
  • 以rRT-PCR为参考,总灵敏度97.5%(91.4-99.7%),特异性99.9%(99.2-100%),总符合率99.6%(98.7-99.9%),Cohen's kappa 0.98(0.96-1)。
  • Ct≤37.8时阳性检出率100%(95.4-100%)。

临床怎么用

  • 该检测可用于大规模人群COVID-19筛查和监测,作为rRT-PCR的替代方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To describe a high-sensitivity SARS-CoV-2 antigen test that is based on the fully automated light-initiated chemiluminescent immunoassay (LiCA®), and to validate its analytical characteristics and clinical agreement on detecting SARS-CoV-2 infection against the reference molecular test. METHODS: Analytical performance was validated and detection limits were determined using different types of nucleocapsid protein samples. 798-pair anterior nasal swab specimens were collected from hospitalized patients and asymptomatic screening individuals. Agreement between LiCA® antigen and real-time reverse transcription polymerase chain reaction (rRT-PCR) was evaluated. RESULTS: Repeatability and within-lab precision were 1.6-2.3%. The C5∼C95 interval was -5.1-4.6% away from C50. Detection limits in average (SD) were 325 (±141) U/mL on the national reference panel, 0.07 (±0.04) TCID50/mL on active viral cultures, 0.27 (±0.09) pg/mL on recombinant nucleocapsid proteins and 1.07 (±1.01) TCID50/mL on inactivated viral suspensions, respectively. LiCA detected a median of 374-fold (IQR 137-643) lower levels of the viral antigen than comparative rapid tests. As reference to the rRT-PCR method, overall sensitivity and specificity were determined to be 97.5% (91.4-99.7%) and 99.9% (99.2-100%), respectively. Total agreement between both methods was 99.6% (98.7-99.9%) with Cohen's kappa 0.98 (0.96-1). A positive detection rate of 100% (95.4-100%) was obtained as Ct≤37.8. CONCLUSIONS: The LiCA® system provides an exceptionally high-sensitivity and fully automated platform for the detection of the SARS-CoV-2 antigen in nasal swabs. The assay may have high potential use for large-scale population screening and surveillance of COVID-19 as an alternative to the rRT-PCR test.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Yu M, Chen D, Tang X, et al. Evaluation of a high-sensitivity SARS-CoV-2 antigen test on the fully automated light-initiated chemiluminescent immunoassay platform. Clin Chem Lab Med. 2023. PMID: 36656975. doi:10.1515/cclm-2022-1039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。